Strongbridge Biopharma plc to Present at the JMP Securities Life Sciences Conference
06 juin 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc to Present at the Jefferies 2018 Global Healthcare Conference
31 mai 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Reports First Quarter 2018 Financial Results and Provides Corporate Update
10 mai 2018 07h30 HE
|
Strongbridge Biopharma plc
~ KEVEYIS® (dichlorphenamide) First Quarter 2018 Revenue of $3.9 Million ~ ~ Increased Full-Year 2018 Revenue Guidance for KEVEYIS from $16 to $19 Million to $18 to $20 Million ~ ~ MACRILEN™...
Strongbridge Biopharma plc Announces New Employment Inducement Awards
03 mai 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., May 03, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc to Host First Quarter 2018 Financial Results Conference Call on May 10, 2018
26 avr. 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., April 26, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
02 avr. 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc to Host Investor and Analyst Day on April 5, 2018
26 mars 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., March 26, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma Announces Issuance of Patent for RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome
20 mars 2018 16h15 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis
18 mars 2018 14h00 HE
|
Strongbridge Biopharma plc
~ Data Suggest Levoketoconazole, the Isolated 2S,4R Enantiomer of Ketoconazole, Accounts for Essentially All of the Inhibition by Ketoconazole of Cortisol Biosynthesis in Humans ~ ~ Results...
Strongbridge Biopharma plc Reports Full-Year 2017 Financial Results
12 mars 2018 07h30 HE
|
Strongbridge Biopharma plc
~ KEVEYIS® (dichlorphenamide) Fourth Quarter and Full-Year 2017 Revenue of $3.0 Million and $7.0 Million, Respectively ~ ~ Full-Year 2018 KEVEYIS Revenue Guidance of $16 to $19 Million ~ ~ MACRILEN™...